ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma
Stefano, Sammicheli, Grandclement, Camille, Dehilly, Elie, Panagopoulou, Maria, Martini, Evangelia, Castillo, Rosa, Suere, Perrine, Pouleau, Blandine, Estoppey, Carole, Frei, Julia, Loyau, Jeremy, Monney, Thierry, Wood, Rebecca, Croset, Amelie, Rubod, Alain, Gudi, Girish, Udupa, Venkatesha, Gn, Sunitha, Menon, Vinu, Rasmussen, Daniel, Olsen, Jeppe Koch, Giovannini, Roberto, Chakrapani, Aravind, Blein, Stanislas, Doucey, Marie-Agnes, Drake, Adam, Riva, Alessandro, Konto, Cyril, Perro, Mario, Mbow, Lamine
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Abstract 2903: ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+ malignancies
Sammicheli, Stefano, Grandclement, Camille, Dheilly, Elie, Panagopoulou, Maria, Martini, Evangelia, Suere, Perrine, Pouleau, Blandine, Estoppey, Carole, Frei, Julia, Loyau, Jeremy, Monney, Thierry, Drake, Adam, Rubod, Alain, Doucey, Marie Agnes, Menon, Vinu, Udupa, Venkatesha, GN, Sunitha, Rasmussen, Daniel, Olsen, Jeppe Koch, Gionannini, Roberto, Gudi, Girish, Srivastava, Ankita, Konto, Cyril, Perro, Mario
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article